Trial Profile
A phase I/II randomized, observer-blind, controlled study to assess safety and immunogenicity of acellular Pertussis vaccine given alone or in combination with Tetanus-diphtheria vaccine in healthy adults aged 18-35 years
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Dec 2017
Price :
$35
*
At a glance
- Drugs Pertussis acellular vaccine (Primary)
- Indications Pertussis
- Focus Adverse reactions
- Sponsors BioNet-Asia
- 28 Nov 2014 New trial record